Compare MS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MS | MRK |
|---|---|---|
| Founded | 1924 | 2000 |
| Country | United States | United States |
| Employees | 83000 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.4B | 268.7B |
| IPO Year | N/A | 1994 |
| Metric | MS | MRK |
|---|---|---|
| Price | $211.63 | $121.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 17 |
| Target Price | ★ $337.93 | $125.59 |
| AVG Volume (30 Days) | 4.8M | ★ 6.9M |
| Earning Date | 04-15-2026 | 04-30-2026 |
| Dividend Yield | 2.14% | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $12.22 | $3.61 |
| Revenue Next Year | $5.62 | $5.41 |
| P/E Ratio | $17.30 | ★ N/A |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $128.81 | $76.66 |
| 52 Week High | $219.16 | $125.14 |
| Indicator | MS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.79 | 60.69 |
| Support Level | $155.16 | $112.49 |
| Resistance Level | N/A | $124.09 |
| Average True Range (ATR) | 5.18 | 2.82 |
| MACD | 1.05 | 0.45 |
| Stochastic Oscillator | 76.54 | 83.03 |
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 82,000 employees as of year-end 2025. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $9.3 trillion in client assets at the end of 2025. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with more than $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).